SHP Shire

TIDMSHP 
 
 
   Shire to announce third quarter 2017 results 
 
   Dublin, Ireland - October 12, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), 
will announce third quarter 2017 earnings on Friday October 27, 2017. 
 
 
 
 
Results press release will be issued at:  12:00 BST / 07:00 EDT 
Investor conference call time:            14:00 BST / 09:00 EDT 
 
   Live conference call for investors: 
 
   Flemming Ornskov, MD, Chief Executive Officer, Jeff Poulton, Chief 
Financial Officer and Matt Walker, Head of Technical Operations will 
host the investor and analyst conference call at 
 
   9:00 EDT / 14:00 BST. 
 
   The details of the conference call are as follows: 
 
 
 
 
UK dial in:    0808 237 0030 or 020 3139 4830 
US dial in:    1 866 928 7517 or 1 718 873 9077 
International  Click here: 
Access         http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Acc 
Numbers:       ess_List.pdf 
Password/Conf  31097524# 
ID: 
Live Webcast:  Click here 
               http://investors.shire.com/presentations-and-reports/quarterly-re 
               sults-and-presentations 
 
   Replay: 
 
   A replay of the presentation will be available for two weeks by phone 
and by webcast for three months.  Replay information can be found on the 
Investor Relations section of Shire's website at 
http://investors.shire.com/. 
 
   For further information please contact: 
 
 
 
 
Investor Relations 
Ian Karp             ikarp@shire.com     +1 781 482 9018 
Robert Coates        rcoates@shire.com   +44 203 5490874 
 
 
   NOTES TO EDITORS 
 
   About Shire 
 
   Shire is the leading global biotechnology company focused on serving 
people with rare diseases and other highly specialized conditions. We 
strive to develop best-in-class products, many of which are available in 
more than 100 countries, across core therapeutic areas including 
Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage 
Disorders, Gastrointestinal / Internal Medicine / Endocrine and 
Hereditary Angioedema; and a growing franchise in Oncology. 
 
   Our employees come to work every day with a shared mission: to develop 
and deliver breakthrough therapies for the hundreds of millions of 
people in the world affected by rare diseases and other high-need 
conditions, and who lack effective therapies to live their lives to the 
fullest. 
 
   www.shire.com 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Shire plc via Globenewswire 
 
 
 
 

(END) Dow Jones Newswires

October 12, 2017 07:15 ET (11:15 GMT)

Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024

Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024